Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · May 11, 2018
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how music therapy can help infants who have Neonatal Abstinence Syndrome (NAS), a condition that affects newborns exposed to certain drugs before birth. The study will test six different types of music therapy to see how they can improve outcomes for these babies while they are receiving care in the Neonatal Intensive Care Unit (NICU).
To participate in this study, infants need to be admitted to the NICU immediately after birth and be at least 28 weeks old. They should not have any hearing problems or certain developmental disabilities. Additionally, a parent or legal guardian must be able to provide consent and complete a brief questionnaire about bonding with their baby. If eligible, participants can expect to experience various music therapy sessions designed to support their recovery from NAS, which may help them feel more comfortable and improve their overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Infants who meet the following inclusion criteria will be eligible to participate in the study irrespective of race, religion, ethnicity, or gender:
- • Admitted to the NICU immediately postpartum
- • Gestational age 28 weeks or older
- • No identified hearing disorder
- • Do not have a diagnosed developmental disability (i.e. Down Syndrome)
- • Do not have Fetal Alcohol Syndrome
- • Medically cleared to participate in the study by nurse or neonatologist
- • Parent or legal guardian able/willing to give consent \& complete the PBQ (Postpartum Bonding Questionnaire)
- Exclusion Criteria:
- • Admitted to the NICU at any time other than immediately postpartum
- • Gestational age \<28 weeks old
- • Has an identified hearing disorder
- • Has diagnosed developmental disability (i.e. Down syndrome)
- • Has Fetal Alcohol Syndrome
- • Is not medically cleared to participate in the study by the nurse or neonatologist
- • Parent or legal guardian unable/unwilling to give consent
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Orleans, Louisiana, United States
Hackensack, New Jersey, United States
New Hyde Park, New York, United States
Valhalla, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Ny, New York, United States
Patients applied
Trial Officials
Joanne Loewy, PhD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Kathy Murphy, PhD
Principal Investigator
Loyola University
Aimee Telsey, MD
Study Director
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials